Reduce Cardiovascular Semaglutide Powder Cas 782487-28-9

Semaglutide is an analog of human glucagon-like peptide-1 produced by yeast through gene recombination technology, and has 94% sequence homology with human GLP-1. It combines diet and exercise to control blood sugar in adult patients with type 2 diabetes. It is administered by subcutaneous injection once a week. The injection site can be the abdomen, thigh or upper arm. The marketed dosage form is injection. This product is an adjustable-dose, disposable pre-filled injection pen, consisting of a pen-type syringe and a pen core containing 1.5 mL of liquid (containing 2 mg of semaglutide).

Semaglutide is the seventh approved GLP-1 receptor agonist in the world after exenatide, liraglutide, abiglutide, dulaglutide, risnaglutide, and benaglutide. Agent. At the same time, it is also known as the best hypoglycemic drug in history.